リキシセナチド
1. LixisenatideLixisenatide is a once-daily injectable GLP-1 receptor agonist that has been developed by Sanofi. As of September 2010 it is in clinical trials for diabetes. Lixisenatide, a glucagon-like peptide-1 agonist (GLP-1), is in development for the treatment of patients with type 2 diabetes mellitus. Lixisenatide was discovered by Zealand Pharma A/S and the global rights are licensed to Sanofi. Lyxumia® is the intended trademark for lixisenatide.
Read “Lixisenatide” on English Wikipedia
Read “リキシセナチド” on Japanese Wikipedia
Read “Lixisenatide” on DBpedia
Read “Lixisenatide” on English Wikipedia
Read “リキシセナチド” on Japanese Wikipedia
Read “Lixisenatide” on DBpedia
Discussions
Log in to talk about this word.